Zeta EBV-LMP Antibody. Zeta’s monoclonal antibody recognizes EBV-LMP, the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A). The EBV-LMP antibody (CS1-4) reacts strongly with EBV-positive lymphoblastoid cell lines and EBV infected B cell immunoblasts in infectious mononucleosis. The EBV-LMP also reacts with 25 to 50 per cent of EBV-associated undifferentiated nasopharyngeal carcinomas and with Reed Sternberg cells in approximately 90% of EBV-associated Hodgkin’s lymphoma cases. The EBV-LMP antibody recognizes distinct epitopes on the hydrophilic carboxyl region of LMP which is exposed to the cytosol.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.